Haloperidol Krka (Haloperidol)

Haloperidol Krka is indicated for the management of several neuropsychiatric disorders where dopamine blockade is beneficial.

• Treatment of schizophrenia in adults and adolescents.
• Control of acute psychotic episodes.
• Management of Tourette syndrome symptoms.
• Adjunct therapy for severe agitation or aggression.
• Short‑term use in postoperative or intensive‑care settings when rapid sedation is required.

Side effects of haloperidol can vary in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor or rigidity.
• Dry mouth.
• Constipation.
• Blurred vision.
• Weight gain.

Serious

• Neuroleptic malignant syndrome.
• Tardive dyskinesia.
• Severe hypotension.
• Cardiac arrhythmias (QT prolongation).
• Hyperprolactinemia leading to hormonal disturbances.

Before starting Haloperidol Krka, clinicians should evaluate patient history and monitor for potential risks.

• Assess cardiovascular status, especially QT interval.
• Review history of movement disorders or Parkinsonian symptoms.
• Use caution in patients with hepatic or renal impairment.
• Monitor for signs of neuroleptic malignant syndrome.
• Evaluate pregnancy or breastfeeding status, as safety data are limited.
• Adjust dose in elderly patients to reduce fall risk.

Haloperidol may interact with several drug classes, influencing efficacy or safety.

Avoid

• Other dopamine antagonists or antipsychotics that increase extrapyramidal risk.
• Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors that raise haloperidol plasma levels.

Use with caution

• CNS depressants such as benzodiazepines or opioids.
• Anticholinergic agents that may mask extrapyramidal signs.
• Drugs affecting electrolyte balance, which can exacerbate cardiac effects.
• Alcohol, due to additive sedation.